Drug Profile

AVC 201

Alternative Names: Allo-RevCAR01-T-CD123; AVC-201

Latest Information Update: 12 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AvenCell Europe
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Cancer

Highest Development Phases

Phase I Acute myeloid leukaemia; Haematological malignancies

Most Recent Events

06 Feb 2024 AvenCell plans a phase II trial for cancer
06 Feb 2024 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in Netherlands (IV) (NCT05949125)
06 Feb 2024 Phase-I clinical trials in Haematological malignancies (Second-line therapy or greater) in Germany, Netherlands (IV) (NCT05949125)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com